3-nitro-4-phenoxypyridine | 132038-21-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-nitro-4-phenoxypyridine
• CAS: 132038-21-2
• 化学式: C₁₁H₈N₂O₃
• mdl: MFCD19690877
• 分子量: 216.196
• InChiKey: SWLYQWDNJRERGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-nitro-4-phenoxypyridine 在 sodium tetrahydroborate 、 10% Pd/C 、 氢气 作用下， 以 甲醇 为溶剂， 生成 3-(2-甲氧基苄氨基)-4-苯氧基吡啶
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093
• 作为产物：
  描述：

  4-羟基-3-硝基吡啶 在 potassium carbonate 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 3-nitro-4-phenoxypyridine
  参考文献：
  名称：

  High colour rendering index and colour stable hybrid white efficient OLEDs with a double emitting layer structure using a single phosphorescence dopant of heteroleptic platinum complexes

  摘要：

  基于铂配合物单掺杂剂的混合白色OLED具有电压独立的CIE和出色的CRI。

  DOI：

  10.1039/c4tc01791a

文献信息

• [EN] GSK-3 INHIBITORS<br/>[FR] INHIBITEURS DE GSK-3
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015069594A1

  公开（公告）日：2015-05-14

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  披露通常涉及到公式I的化合物，包括它们的盐，以及使用这些化合物治疗与GSK-3相关疾病的组合物和方法。
• Phenoxypyridinamine compounds which are use as a dermatological
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04959377A1

  公开（公告）日：1990-09-25

  There are described compounds of the formula ##STR1## where n is 0 or 1; X is hydrogen, loweralkyl, loweralkoxy, halogen, formyl, loweralkylcarbonyl, loweralkyoxycarbonyl, loweralkoxycarbonylloweralkyl or hydroxymethyl; Y is hydrogen or halogen;and R is hydrogen, loweralkyl arylloweralkyl or loweralkylcarbonyl, which compounds are useful as topical antiinflammatory agents for the treatment of various dermatoses.

  描述了一种化合物，其化学式为##STR1##其中n为0或1；X为氢、较低的烷基、较低的烷氧基、卤素、甲酰基、较低的烷基羰基、较低的烷氧羰基、较低的烷氧羰基较低的烷基或羟甲基；Y为氢或卤素；R为氢、较低的烷基芳基较低的烷基或较低的烷基羰基，这些化合物可用作治疗各种皮肤病的局部抗炎药。
• Novel 2,4,5-Trisubstituted Pyridines as Key Intermediates for the Preparation of the TSPO Ligand 6-F-PBR28: Synthesis and Full¹H and¹³C NMR Characterization
  作者：Annelaure Damont、Frédéric Lemée、Guillaume Raggiri、Frédéric Dollé

  DOI：10.1002/jhet.1723

  日期：2014.3

  As part of our ongoing research for molecular structures binding to the translocator protein (TSPO 18 kDa), we investigated the preparation of a number of new 2,4,5‐trisubstituted pyridines as novel building blocks. In particular, 5‐amino‐2‐halo‐4‐phenoxypyridines (11, 12, 13) were designed as key intermediates for the synthesis of the recently developed TSPO ligand 6‐F‐PBR28 and its fluorine‐18‐labeled

  作为我们正在进行的与转运蛋白（TSPO 18 kDa）结合的分子结构研究的一部分，我们研究了许多新的2,4,5-三取代吡啶作为新型结构单元的制备。特别是，5-氨基-2-卤代-4- phenoxypyridines（11，12，13）被设计为关键中间体，用于最近开发的TSPO的合成配体6-F-PBR28及其用于正电子氟-18标记的版本放射断层扫描，6‐ [ 18 F] F‐PBR28。我们在此报告的化学制剂以及1 H和13个取代的吡啶的C NMR光谱数据2，3，4，5，6，7，图7b，8，9，10，11，12，13，14。后者证明了芳环在取代时电子密度的重新分配发生了戏剧性的变化。
• GSK-3 INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160272621A1

  公开（公告）日：2016-09-22

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  本发明涉及公式I的化合物及其盐，以及使用这些化合物治疗与GSK-3相关的疾病的组合物和方法。
• Phenoxypyridinamines and related compounds, a process for their preparation and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0405487A1

  公开（公告）日：1991-01-02

  The present invention relates to compounds of the formula where n is 0 or 1; X is hydrogen, loweralkyl, loweralkoxy, halogen, formyl, loweralkylcarbonyl, loweralkoxycarbonyl, loweralkoxycarbonylloweralkyl or hydroxymethyl; Y is hydrogen or halogen; Z is NO₂ or NHR, were R is hydrogen, loweralkyl, arylloweralkyl or loweralkylcarbonyl, and to a process for their preparation. The compounds are useful as topical antiinflammatory agents for the treatment of various dermatoses.

  本发明涉及式如下的化合物 式中 n 是 0 或 1； X是氢、低级烷基、低级烷氧基、卤素、甲酰基、低级烷基羰基、低级烷氧基羰基、低级烷氧基羰基低级烷基或羟甲基； Y 是氢或卤素 Z 是 NO₂ 或 NHR，其中 R 是氢、低级烷基、芳基低级烷基或低级烷基羰基、 及其制备工艺。这些化合物可用作治疗各种皮肤病的局部消炎剂。